Update on recent clinical trials in congestive heart failure

Current Opinion in Cardiology

Volumn 15, Issue 4, 2000, Pages 293-303

  Betkowski, Adam S ^a   Hauptman, Paul J ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENALAPRIL; HYDRALAZINE; IBOPAMINE; ISOSORBIDE DINITRATE; LEVOSIMENDAN; LISINOPRIL; LOSARTAN; METOPROLOL; MILRINONE; MOXONIDINE; PIPERANOMETOZINE; PRACTOLOL; PRAZOSIN; RAMIPRIL; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VALSARTAN; VASOPRESSIN ANTAGONIST; XAMOTEROL;

CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPOTENSION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; STIMULATION, CHEMICAL; SYMPATHOLYTICS;

EID: 0033916169     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200007000-00015     Document Type: Review

References (85)

1. 1 Mann DL: Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999, 100:999-1008. Excellent in-depth review of heart failure pathophysiology and strategies for new therapies.
2. 2 Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995, 273:1450-1456.
3. 3 CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
4. 4 SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991, 325:293-302.
5. 5 Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. The results of the Survival and Ventricular Enlargement (SAVE) trial. N Engl J Med 1992, 327:669-677.
6. 6 AIRE (Acute Infarction Ramipril Efficacy) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342:821-828.
7. 7 Packer M, Cohn J, for the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure: Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999, 83(2A):1A-38A.
8. 8 Packer M, Poole-Wilson P, Armstrong P, et al., on behalf of the ATLAS Study Group: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999, 100:2312-2318. New data indicating benefits of a high dose ACE inhibitor over a low dose therapy in heart failure patients.
9. 9 The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153. New data showing effectiveness of ACE inhibitor therapy on reducing cardiovascular events in high-risk patients without known low ejection fraction or heart failure.
10. 10 Weber KT, Villareal D: Aldosterone and anti-aldosterone therapy in congestive heart failure. Am J Cardiol 1993, 71:3A-11A.
11. 11 Struthers AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy In chronic heart failure. J Cardiac Fail 1996, 2:47-54.
12. 12 Barr CS, Lang CC, Hanson J, et al.: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259-1265.
13. 13 Pitt B, Zannad F, Remme WJ, et al., for the Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717. New data demonstrating effectiveness of spironolactone in reducing mortality and morbidity in patients with severe heart failure receiving standard triple therapy.
14. 14 Weber KT: Aldosterone and spironolactone in heart failure [editorial]. N Eng J Med 1999, 341:753-755.
15. 15 Zannad F, Alla F, Dousset B, Pitt B: Survival benefits if spironolactone therapy may be explained by the limitation of the excessive extracellular matrix turnover in patients with CHF: insights from the RALES Trial [abstract]. J Am Coll Cardiol 2000, 35(suppl. A): 203A.
16. 16 Searle healthNet/Press Releases. Jan. 26, 2000 http:www.searlehealth-net.com/pr/pr012600.html.
17. 17 Roig E, Perez-Villa F, Morales M, et al.: Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000, 21:53-57.
18. 18 Coulter DM, Edwards IR: Cough associated with captopril and enalapril. Br Med J 1987, 294:1521-1523.
19. 19 Struthers AD: Angiotensin II receptor antagonists for heart failure. Heart 1998, 80:5-6.
20. 20 Pitt B, Segal R, Martinez FA, et al., on behalf of ELITE Study Investigators: Randomized trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997, 349:747-752.
21. 21 ELITE II Investigators: Late breaking clinical trials. American Heart Association Scientific Session. 1999 Atlanta, Georgia.
22. 22 Cohn JN: ELITE II results (Editorial) Val-HeFT International Letter. December 1999;6.
23. 23 Tsuyuki RT, Yusuf S, Rouleau JL, et al., for the RESOLVD Pilot Study Investigators: Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997, 13(12):1166-1174.
24. 24 Yusuf S: Randomized Evaluation of Strategies for the Left Ventricular Dysfunction Results: Late breaking clinical trials. American Heart Association Scientific Session, 1997 Orlando, Florida.
25. 25 Cohn JN, Tognoni G: Val-HeFT-Valsartan in heart failure trial: population characteristics [abstract]. J Am Coll Cardiol 2000, 35(Suppl. A):211A.
26. 26 Cohn JN, Tognoni G, Glazer RD, et al.: Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999, 5:155-160.
27. 27 Califf RM, Cohn JN: Cardiac protection: evolving role of angiotensin receptor blockers. Am Heart J 2000, 139:S15-S22.
28. 28 Dickstein K, Kjeshus J, for the OPTIMAAL study group: Comparison of the effects of losartan and captopril on mortality in patients following acute myocardial infarction: the OPTIMAAL trial design. Optimal Trial In Myocardial infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 1999, 83:825-881.
29. 29 Pfeffer MA: Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers. Am Heart J 2000, 139:S23-S28.
30. 30 Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I: Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975, 37:1022-1036.
31. 31 Cohn JN, Levine B, Olivari MT, et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Eng J Med 1984, 311:819-823.
32. 32 Bristow MR, Ginsburg R, Umans V, et al.: Beta 1 and beta 2-adrenergic subpopulations in nonfailing and failing human myocardium: coupling of both receptor subtypes to muscle contraction and selective beta-1 receptor downregulation in heart failure. Cir Res 1989, 59:297-309.
33. 33 Heidenreich PA, Lee TT, Massie BM: Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997, 30:27-34.
34. 34 Lechat P, Packer M, Chalon S, et al.: Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998, 98:1184-1191.
35. 35 Packer M, Bristow MR, Cohn JN, et al., for the U.S. Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355. Data from studies indicating significant benefits of carvedilol on mortality, morbidity, and ejection fraction.
36. 36 Waagstein F, Bristow MR, Swedberg K, et al., for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993, 342:1441-46.
37. 37 CIBIS Investigators and Committees: A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study. Circulation 1994, 90:1765-1773.
38. 38 Colucci WS, Packer M, Bristow MR, et al., for the US Heart Failure Study Group: Carvedilol inhibits clinical progression in patients with mild symptoms of Heart Failure. Circulation 996, 94:2800-2806.
39. 39 Packer M, Colucci WS, Sackner-Bernstein JD, et al., for the PRECISE Study Group: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Circulation 1996, 94:2793-2799.
40. 40 Cohn JN, Fowler MB, Bristow MR, et al., for the Carvedilol Heart Failure Study Group: effect of carvedilol in severe chronic heart failure [abstract], J Am J Cardiol 1996, 27:169A.
41. 41 Bristow MR, Gilbert EM, Abraham WT, et al., for the MOCHA Investigators: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94:2807-2816.
42. 42 Australia/New Zealand Heart Failure Research Collaborative Group: Randomized, placebo controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997, 349:375-380.
43. 43 Richards AM, Doughty R, Nicholls MG, et al., for the Australia-New Zealand Heart Failure Group: Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999, 99:786-792.
44. 44 MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007. Data from the study demonstrating benefits of metoprolol CR/XL on survival and morbidity in patients with heart failure.
45. 45 CIBIS-II Investigators and Committees: The cardiac insufficiency Study II (CIBIS-II): a randomized trial. Lancet 1999, 353:9-13. Data from the study showing benefits of bisoprolol on mortality and morbidity in heart failure patients.
46. 46 Progress in Clinical Trials: BEST (Beta blocker Evaluation of Survival Trial). Clin Cardiol 2000, 23:56-58.
47. 47 Bristow MR: Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558-569. Excellent in-depth review of the role of beta-adrenergic blockade in heart failure.
48. 48 Cohn LN: Late-breaking clinical trials presented new research: MOXCON Heart Failure Society News Dec. 1999/Jan 2000, 2:5.
49. 49 Cohn JN, Archibald DG, Ziesche S, et al.: Effects of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986, 314:1547-1552.
50. 50 Ferguson DW: Digitalis and neurohormonal abnormalities in heart failure and implications for therapy. Am J Cardiol 1992, 69(suppl):24G-32G.
51. 51 The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533. Data from the large study showing neutral effect of digoxin on mortality but beneficial effect on morbidity.
52. 52 Funk M: Epidemiology of end-stage heart disease. In: The Artificial Heart: Prototypes, Policies, and Patients. Edited by Hogness JR, Van Antwerp M. Washington, D.C.: National Academic Press, 1991:251-261.
53. 53 Dies F, Krell MJ, Whitlow P, et al.: Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [abstract]. Circulation 1986, 74(suppl 11):11-38.
54. 54 The Xamoterol in Severe Heart Failure Study Group: Xamoterol in severe heart failure. Lancet 1990, 336:1-6.
55. 55 Hampton JR, van Veldhuisen DJ, Kleber FX, et al., for the Second Prospective Randomized Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators: Randomized study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997, 349:971-977.
56. 56 Packer M, Carver JR, Rodeheffer RJ, et al., for the PROMISE Study Research Group: Effects of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991, 325:1468-1475.
57. 57 Cohn JN, Goldstein SO, Greenberg BH, et al., for the Vesnarinone Trial Investigators: A dose-dependant increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998, 339:1810-1816.
58. 58 Packer M, Rouleau JL, Swedberg K, et al., for the PROFILE Investigators and Coordinators: Effects of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study [abstract]. Circulation 1993, 88(suppl 1):1-301.
59. 59 Gheorghiade M: Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure: OPTIME-CHF. Late-Breaking Clinical Trial Results. American College of Cardiology Scientific Session 2000, Anaheim, CA.
60. 60 Papp JG: Positive inotropy by calcium sensitization: an evolving approach for the treatment of end-stage heart failure. Am J Cardiol 1999; 83(12B):11-13.
61. 61 Follath F, Cleland JFG, Just H, et al.: Efficacy and safety of intravenous levosimendan in severe low out-put heart failure: a randomized, double-blind comparison to dobutamine (the LIDO Study) [abstract]. J Card Fail 1999, 5(suppl 1):57.
62. 62 Cleland JFG, Follath F: LIDO trial results. Late breaking clinical trial session. 3rd Annual Scientific Meeting of the Heart Failure Society of America. San Francisco, September 23, 1999.
63. 63 Moiseyev VS, Andrejevs N, Lehtonen LA, et al.: The RUSSLAN Study Group: randomized study on safety and effectiveness of levosimendan in patients with left ventricular failure after an acute myocardial infarction [abstract] J Card Fail 1999, 5(suppl 1):43.
64. 64 Figulla HR, Gietzen F, Zeymer U, et al., for the DiDi Study Group: Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 1996, 94:3467-3352.
65. 65 Packer M, O'Connor CM, Ghali JK, et al., for the Prospective Randomized Amlodipine Survival Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996, 335:1107-1114.
66. 66 Cohn JN, Ziesche S, Smith R, et al., for the Vasodilator-Heart Failure (V-HeFT) Study Group. Effects of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HEFT III. Circulation 1997;96: 856-863
67. 67 Levine TB, Bernink PJLM, Caspi A, et al.: Effect of mibefradil, a T-type calcium channel blocker on morbidity and mortality in moderate to severe congestive heart failure. The MACH-1 Study. Circulation 2000, 101:758-764.
68. 68 Packer M: Prospective Randomized Amlodipine Survival Study-2. Late-breaking clinical trial results. American College of Cardiology Scientific Session, 2000, Anaheim, CA.
69. 69 Kostis JB, Rouleau JL, Pfeffer MA, et al., for the Omapatrilat Heart Failure Investigators: Beneficial effects of vasopeptidase inhibition on mortality and morbidity in heart failure: evidence from the Omapatrilat Heart Failure Program [abstract]. J Am Coll Cardiol 2000, 35(suppl A):240A.
70. 70 Bozkurt B, Torre-Amione G, Soran OZ, et al.: Safety and efficacy of ENBREL (Etanercept) in the treatment of chronic heart failure [abstract]. J Am Coll Cardiol 2000, 35(suppl A):240A.
71. 71 Aukrust P, Ueland T, Lien E, et al.: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999, 83:376-382.
72. 72 Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341:577-585. Comprehensive review of neurohumoral changes in heart failure.
73. 73 Abraham WT, Lowes BD, Ferguson DA, et al.: Systemic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998, 4:37-44.
74. 74 Szatalowicz VL, Arnold PE, Chaimovitz C, et al.: Radio immunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981, 305:263-266.
75. 75 Abraham WT, Oren RM, Crisman TS, et al.: Effects of an oral, nonpeptide, selective V2 receptor antagonist in patients with chronic heart failure [abstract]. J Am Coll Cardiol 1997, 29(suppl A):169A.
76. 76 Benigni A, Remuzzi G: Endothelin antagonists. Lancet 1999, 353:133-138.
77. 77 McNamara D: IMAC: Late-breaking clinical trial session. 3rd Annual Scientific Meeting of the Heart Failure Society of America. San Francisco, September 23, 1999.
78. 78 Gullestad L, Aass H, Fjeld J, et al.: Effect of immunomodulating therapy with intravenous immunoglobulin in chronic heart failure [abstract]. J Am Coll Cardiol 2000, 35(suppl A):240A.
79. 79 Dunkman WB, Johnson GR, Carson PE, et al.: Incidence of thromboembolic events in congestive heart failure. Circulation 1993, 87:VI94-VI101.
80. 80 Loh E, Sutton MS, Wun CC, et al.: Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 997, 336:251-257.
81. 81 Cleland JGF: Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol 1997, 12:276-287.
82. 82 Massie B, Armstrong P, Cleland JGF, et al.: Warfarin and antiplatelet therapy study in chronic heart failure (WATCH): trial design [abstract]. J Card Fail 1999, 5(suppl 1):48.
83. 83 The WASH Study Committee and Investigators: The WASH Study (Warfarin/Aspirin Study in Heart Failure) rationale, design and end-points. Eur J Heart Failure 1999, 1:95-99.
84. 84 Brady GH, Kerry LL, Mark DB, et al., and the SCD-HeFT Pilot Investigators: Sudden Cardiac Death in Heart Failure trial pilot study [abstract]. PACE 1997, 20(II):1148.
85. 85 The Large State Peer Review Organization Consortium: Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. Arch Intern Med 1997, 157:1103-1108.